People · Operator
Named in public records as an officer, director or promoter · active 2014–2017 · Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ovid Therapeutics Inc. | — | Pharma | Series C | $105.9M | $907.5M | 2014 |
Matthew J. During at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Matthew J. During on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Douglas E. Williams | 1 | 4 |
| Jeremy M. Levin | 1 | 1 |
| Mark M. Feldberg | 1 | 1 |
| Yaron M. Werber | 1 | 1 |
| Amit E. Rakhit | 1 | 1 |
| Bart M. Friedman | 1 | 1 |
| Karen E. Bernstein | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.